Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-06-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
独立董事提名人声
Board/Management Information Classification · 95% confidence The document is a nomination statement for an independent director candidate for the company's board. It details the qualifications, independence criteria, and legal compliance of the nominee. There is no financial data, no report or results announcement, no meeting materials, and no regulatory filing of financial nature. This is a management-related announcement concerning board composition and director nomination. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused solely on the nomination statement, confirming it is not a full report or other category.
2023-06-28 Chinese
关于继续实施稳定股价方案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the continuation of a stock price stabilization plan. It details the conditions triggering the plan, the measures to be taken by directors and senior management to increase their shareholdings, and the constraints and legal compliance related to the plan. The document does not contain financial statements or detailed financial performance data but rather focuses on corporate actions related to shareholding and stock price stabilization. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about capital market activities and shareholding behavior by insiders to stabilize stock price. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-06-28 Chinese
关于重新签署募集资金四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the re-signing of a fundraising supervision agreement related to the company's recent public stock issuance. It details the amount raised, the use of funds, and the signing of a four-party supervision agreement for the raised funds. The document does not contain financial statements or detailed financial performance data but focuses on capital raising and regulatory compliance related to the fundraising. The document length is short (1407 characters) and is clearly an announcement about fundraising activities and agreements. Therefore, it fits best under Capital/Financing Update (CAP).
2023-06-20 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Beijing Health Guard Biotechnology Inc. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, shareholder meetings, share issuance, share transfer, and other governance-related rules. It references the company's registration, listing on the Beijing Stock Exchange, and compliance with relevant laws and regulations. The content is focused on the internal rules and governance framework of the company rather than financial performance, audit results, or meeting announcements. This type of document fits the definition of Governance Information (CGR), which details the company's internal rules, board structure, and governance practices. The document length is substantial and contains the full text of the governance charter, not just an announcement or summary. Therefore, the appropriate classification is CGR with high confidence.
2023-06-18 Chinese
关于完成工商变更登记及公司章程备案并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the completion of industrial and commercial registration changes and the filing of the company's articles of association, along with obtaining a new business license. It details changes in registered capital and total shares, referencing relevant laws and previous announcements. The document is short (1164 characters) and serves as a formal notification of corporate registration updates rather than a financial report or detailed management discussion. It does not contain financial statements, audit information, or detailed governance reports but rather a regulatory update on company registration and capital changes. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2023-06-18 Chinese
独立董事关于第四届董事会第二十次会议审议事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including approval of fundraising project implementation, stock repurchase and cancellation related to equity incentive plans, and proposed changes to registered capital and company bylaws. It references a specific board meeting date (June 12, 2023) and discusses compliance with stock exchange listing rules and regulatory guidelines. The document is a formal announcement of independent directors' opinions on board resolutions, not a full report or financial statement. It is not an annual or interim report, earnings release, or proxy solicitation. The content fits best under Board/Management Information (MANG) as it relates to board meeting decisions and governance matters. The document length is short and focused on board opinions, confirming it is not a full report or presentation.
2023-06-12 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.